Completion of Lilly’s Alzheimer’s submission slips out of Q1 after CMS’ Aduhelm decision Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months after posting weak colitis data Sponsored: Taking a Different Approach to Drug Development J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset Sponsored: Choose wisely. Biospecimens can make or break your biomarker-driven cancer research Intellia Rewrites pipeline expansion in $200M acquisition of UC Berkeley DNA writing startup AstraZeneca punts midphase cardiovascular prospect to startup J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets Amgen enters hot protein degradation field with $500M biobucks deal with Plexium Dewpoint, with a handful of Big Pharma partners from Merck to Pfizer, collects $150M to advance its 20 programs After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year BD doubles COVID sales forecast for 2022 even as steep testing dropoff leads to revenue loss Medicare to cover at-home COVID-19 tests this spring after backlash from lawmakers Cancer screening 'not elective,' says president's cancer panel, as it pushes for better awareness Featured Story | By Annalee Armstrong The timeline for completing an accelerated approval request for Eli Lilly’s Alzheimer’s treatment donanemab has slipped out of the first quarter after the Centers for Medicare & Medicaid Services narrowed coverage for Biogen's rival med to just clinical trial use. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Pfizer has accused two former employees who went on to form a new biotech of stealing “the hard work” of the Big Pharma’s own scientists for a diabetes and obesity program, according to a lawsuit filed Wednesday. read more By Nick Paul Taylor Roche’s gut disease prospect etrolizumab has reached the end of the line. After riding out disappointing data in a related indication, Roche has now brought the ax down on a phase 3 program that was testing the antibody in Crohn’s disease patients. read more Sponsored by: TD2 Dive into the unique history of TD2 and learn how their approach to cancer drug development impacts clinical and partner success. read more By Kyle LaHucik Johnson & Johnson said it will discontinue development of bermekimab in atopic dermatitis, which it paid $750 million for, but it will continue investigating the monoclonal antibody in another skin disease. read more Sponsored by: Precision for Medicine Advances in cancer biomarker discovery, validation and clinical applications hinge on one critical resource: Quality biospecimens. Optimize and accelerate program success by sourcing and selecting the right samples. read more By Kyle LaHucik Intellia Therapeutics acquires a little-known University of California, Berkeley startup for up to $200 million that says it can work on gene editing in non-dividing cell types. read more By Nick Paul Taylor AstraZeneca has offloaded a midphase cardiovascular disease drug to Regio Biosciences. After getting a look at phase 2a data on MEDI5884, AstraZeneeca has decided to license the antibody to the startup for use in a peripheral artery disease study. read more By Kyle LaHucik Johnson & Johnson's Janssen unit will pay $40 million upfront and up to $1 billion in biobucks for access to Mersana Therapeutics' antibody-drug conjugate tech for three targets. Following their preclinical collaboration, Janssen will handle clinical trials and commercialization. read more By Kyle LaHucik Amgen is getting into the protein degradation space in a $500 million biobucks deal with biotech startup Plexium. The licensing deal gives Amgen access to two initial programs with the option to add more in the multi-year collaboration. read more By Kyle LaHucik Pfizer, Merck, Bayer and Volastra have already partnered with Dewpoint Therapeutics across neuromuscular conditions, HIV, cancer metastasis and cardiopulmonary diseases. Now, the Boston biotech has an additional $150 million to bankroll 20 pipeline programs. read more By Eric Sagonowsky Before Biogen won approval for controversial Alzheimer's disease drug Aduhelm, the company had been facing down competitive threats to key medicines. Now that Aduhelm is on the market and barely generating any sales, the company could be in an even more challenging position than it was before. read more By Andrea Park Nearly two full years into the pandemic, COVID-19 still has the power to make or break a company’s bottom line. read more By Robert King CMS announced a new initiative to cover at-home COVID-19 tests for Medicare beneficiaries starting this spring after a request from Democratic senators. read more By Ben Adams President Joe Biden's cancer panel says COVID-19 has allowed cancer screening to falsely become an elective option and is urging better communication about its necessity. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 16-17, 2022 | Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Biotech Summit October 10-11, 2022 | Location TBD Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Virtual Event Fierce New Product Planning Summit November 30 - December 1, 2022 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Boston, MA Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 